A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer

por Gartner, Elaina M., Silverman, Paula, Simon, Michael, Flaherty, Lawrence, Abrams, Judith, Ivy, Percy, LoRusso, Patricia M.
Publicado 2011

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (...

por Patel, Sapna, Milhem, Mohammed, Hallmeyer, Sigrun, Daniels, Gregory, Cranmer, Lee, Taback, Bret, Flaherty, Lawrence, Aung, Sandra, Lowder, James, Sharfman, William
Publicado en J Immunother Cancer (2014)

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Al...

por Atkins, Michael B., Hsu, Jessie, Lee, Sandra, Cohen, Gary I., Flaherty, Lawrence E., Sosman, Jeffrey A., Sondak, Vernon K., Kirkwood, John M.
Publicado 2008

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

por Flaherty, Keith T., Lee, Sandra J., Zhao, Fengmin, Schuchter, Lynn M., Flaherty, Lawrence, Kefford, Richard, Atkins, Michael B., Leming, Philip, Kirkwood, John M.
Publicado en J Clin Oncol (2013)

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma

por Samlowski, Wolfram E., Moon, James, Witter, Merle, Atkins, Michael B., Kirkwood, John M., Othus, Megan, Ribas, Antoni, Sondak, Vernon K., Flaherty, Lawrence E.
Publicado en Cancer Med (2017)

A STUDY OF PACLITAXEL, CARBOPLATIN, AND BORTEZOMIB IN THE TREATMENT OF METASTATIC MALIGNANT MELANOMA: A PHASE II CONSORTIUM STUDY

por Croghan, Gary A., Suman, Vera J., Maples, William J., Albertini, Mark, Linette, Gerald, Flaherty, Lawrence, Eckardt, John, Ma, Cynthia, Markovic, Svetomir N., Erlichman, Charles
Publicado 2010

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution

por SUKARI, AMMAR, NAGASAKA, MISAKO, ALHASAN, ROBA, PATEL, DHAVAL, WOZNIAK, ANTOINETTE, RAMCHANDREN, RADHAKRISHNAN, VAISHAMPAYAN, ULKA, WEISE, AMY, FLAHERTY, LAWRENCE, JANG, HYEJEONG, KIM, SEONGHO, GADGEEL, SHIRISH
Publicado en Anticancer Res (2019)

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

por Margolin, Kim A., Moon, James, Flaherty, Lawrence E., Lao, Christopher D., Akerley, Wallace L., Othus, Megan, Sosman, Jeffrey A., Kirkwood, John M., Sondak, Vernon K.
Publicado 2012

SWOG S0215: A Phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

por Livingston, Robert B., Barlow, William E., Kash, Joseph J., Albain, Kathy S., Gralow, Julie R., Lew, Danika L., Flaherty, Lawrence E., Royce, Melanie E., Hortobagyi, Gabriel N.
Publicado 2011

A Phase II Trial of Complete Resection for Stage IV Melanoma: Results of Southwest Oncology Group (SWOG) Clinical Trial S9430

por Sosman, Jeffrey A., Moon, James, Tuthill, Ralph J., Warneke, James A., Vetto, John T., Redman, Bruce G., Liu, P.Y., Unger, Joseph M., Flaherty, Lawrence E., Sondak, Vernon K.
Publicado 2011

A Phase II Study of RO4929097 Gamma-Secretase Inhibitor in Metastatic Melanoma: SWOG 0933

por Lee, Sylvia M., Moon, James, Redman, Bruce G., Chidiac, Tarek, Flaherty, Lawrence E., Zha, Yuanyuan, Othus, Megan, Ribas, Antoni, Sondak, Vernon K., Gajewski, Thomas F., Margolin, Kim A.
Publicado en Cancer (2014)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer...

por Lum, Lawrence G., Al-Kadhimi, Zaid, Deol, Abhinav, Kondadasula, Vidya, Schalk, Dana, Tomashewski, Elyse, Steele, Patricia, Fields, Kristie, Giroux, Melissa, Liu, Qin, Flaherty, Lawrence, Simon, Michael, Thakur, Archana
Publicado en J Immunother Cancer (2021)

Phase II Trial of Combination Thalidomide plus Temozolomide in Patients with Metastatic Malignant Melanoma: Southwest Oncology Group S0508

por Clark, Joseph I., Moon, James, Hutchins, Laura F., Sosman, Jeffrey A., Kast, W. Martin, Da Silva, Diane M., Liu, P.Y., Thompson, John A., Flaherty, Lawrence E., Sondak, Vernon K.
Publicado 2010

Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-negative Melanoma: Long-Term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival

por Carson, William E., Unger, Joseph M., Sosman, Jeffrey A., Flaherty, Lawrence E., Tuthill, Ralph J., Porter, Mark J., Thompson, John A., Kempf, Raymond A., Othus, Megan, Ribas, Antoni, Sondak, Vernon K.
Publicado 2014

A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin): A Southwest Oncology Group Study (S0331)

por Samlowski, Wolfram E., Moon, James, Tuthill, Ralph J., Heinrich, Michael C., Balzer-Haas, Naomi S., Merl, Stuart A., DeConti, Ronald C., Thompson, John A, Witter, Merle T., Flaherty, Lawrence E., Sondak, Vernon K.
Publicado 2010

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

por Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
Publicado en J Immunother Cancer (2018)

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases

por In, Gino K., Poorman, Kelsey, Saul, Michelle, O’Day, Steven, Farma, Jeffrey M., Olszanski, Anthony J., Gordon, Michael S., Thomas, Jacob S., Eisenberg, Burton, Flaherty, Lawrence, Weise, Amy, Daveluy, Steven, Gibney, Geoffrey, Atkins, Michael B., Vanderwalde, Ari
Publicado en Oncotarget (2020)

Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With...

por Flaherty, Lawrence E., Othus, Megan, Atkins, Michael B., Tuthill, Ralph J., Thompson, John A., Vetto, John T., Haluska, Frank G., Pappo, Alberto S., Sosman, Jeffrey A., Redman, Bruce G., Moon, James, Ribas, Antoni, Kirkwood, John M., Sondak, Vernon K.
Publicado en J Clin Oncol (2014)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (procliv...

por Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
Publicado en J Immunother Cancer (2014)

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

por Sosman, Jeffrey A., Carrillo, Carole, Urba, Walter J., Flaherty, Lawrence, Atkins, Michael B., Clark, Joseph I., Dutcher, Janet, Margolin, Kim A., Mier, James, Gollob, Jarod, Kirkwood, John M., Panka, David J., Crosby, Nancy A., O’Boyle, Kevin, LaFleur, Bonnie, Ernstoff, Marc S.
Publicado 2008